Shire returns rights to M 923 biosimilar of Humira (adalimumab) to Momenta Pharmaceuticals.
Momenta Pharmaceuticals, Inc.has announced that Shire has exercised its right to terminate its collaboration agreement with the Company to develop and commercialize M 923, a proposed biosimilar of Humira (adalimumab), based on a comprehensive portfolio assessment following the acquisition of Baxalta.
Under the terms of the 2011 collaboration agreement, the agreement will terminate twelve months following the notice and Shire will continue to be obligated to fund the M 923 program until termination. Shire will begin to work to transfer all ongoing clinical, regulatory and commercialization activities to Momenta at the end of 2016.
Comment: M 923 is currently in a Phase III pivotal trial in patients with chronic plaque psoriasis to compare the safety, efficacy and immunogenicity of M 923 with Humira.
910 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.